Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 7/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617789 | 1.00 | FGFR1 (0.43) | FGFR1FGFR2CCNKCDK12MAP4K1 | |
| Hydrochloric Acid SCHEMBL30991387 | 0.98 | FGFR1 (0.42) | FGFR1FGFR2CCNKCDK12MAP4K1 | |
| SCHEMBL29850702 | 0.80 | DAO (0.46) | ALDH1A1ALOX15HSD17B10KDM4EHPGD | |
| SCHEMBL2995033 | 0.80 | DAO (0.46) | ALDH1A1ALOX15HSD17B10KDM4EHPGD | |
| SCHEMBL14311952 | 0.80 | BACE1 (0.39) | CCNKCDK12NUDT1SYK | |
| SCHEMBL29519596 | 0.80 | BACE1 (0.39) | CCNKCDK12NUDT1SYK | |
| SCHEMBL31726928 | 0.80 | MAP4K1 (0.43) | FGFR1FGFR2CCNKCDK12MAP4K1 | |
| Dimethylformamide SCHEMBL27861446 | 0.80 | DAO (0.38) | ALDH1A1CYP1A2ALOX15HSD17B10KDM4E | |
| SCHEMBL28021323 | 0.79 | NUDT1 (0.46) | FGFR1FGFR2CCNKCDK12NUDT1 | |
| SCHEMBL18969568 | 0.79 | ABL1 (0.47) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964627-A | Preparation method of key intermediate of rebaudinib | 山东铂源药业股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | claimed |
| WO-2023066350-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADING AGENT DEVELOPED ON THE BASIS OF LIGAND COMPOUND, AND THEIR APPLICATIONS | 标新生物医药科技(上海)有限公司 | 2023-04-27 | — | — | WO | claimed |
| CN-116003418-A | CRBN E3 ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-04-25 | — | — | CN | claimed |
| CN-114456180-A | Compound for treating and/or preventing malignant tumor, pharmaceutical preparation and application | 贵州大学 | 2022-05-10 | — | — | CN | claimed |
| CN-110357889-B | Protein degradation targeting compound, anti-tumor application thereof, intermediate thereof and application of intermediate | 上海科技大学 | 2022-03-15 | — | — | CN | claimed |
| WO-2019196812-A1 | PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE | 上海科技大学 | 2019-10-17 | — | — | WO | claimed |
| EP-2900670-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | claimed |
| EP-2536730-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | Novartis AG (CH) | 2012-12-26 | — | — | EP | claimed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | claimed |
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2025-02-27 | — | — | US | disclosed |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | SHANGHAITECH UNIVERSITY (CN) | 2025-02-18 | — | — | US | disclosed |
| WO-2024249554-A1 | MULTITARGET SMALL MOLECULE INHIBITORS AND USES THEREOF | THE CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY D/B/A ATRIUM HEALTH (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-117964627-A | Preparation method of key intermediate of rebaudinib | 山东铂源药业股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2024086361-A1 | MOLECULAR GLUE DEGRADER COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-04-25 | — | — | WO | disclosed |
| CN-103201275-A | Salts of 7-cyclopentyl-2- (5-piperazin-1-yl-pyridin-2-ylamino) -7H-pyrrolo [2,3-D ] pyrimidine-6-carboxylic acid dimethylamide and methods of making the same | NOVARTIS AG | 2013-07-10 | — | — | CN | disclosed |
| EP-2536730-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | Novartis AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| EP-2331547-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | FGFR1 3627/4885FGFR2 3465/4885CCNK 1299/4885 |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | UFM1, SUMO1, SUMO2 | FGFR1 3615/4885FGFR2 3458/4885CCNK 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.